Author Archives: admin


Stem Cell Clinic > Articles by: admin

Somatic Stem Cells | SpringerLink

By Somatic Stem Cells

Stem cells are found in almost all organisms from the early stages of development to the end of life. There are several types of stem cells and all of them may prove useful for medical research; however, each of the different types has both promise and limitations. Somatic Stem Cells: Methods and Protocols presents selected genetic, molecular, and cellular techniques used in somatic stem cell research and its clinical application. Chapters focus on the isolation, characterization, purity, plasticity, and clinical uses of somatic stem cells from a variety of human and animal tissues. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls.

Through and intuitive, Somatic Stem Cells: Methods and Protocols seeks to provides scientists with the fundamental techniques of stem cell research and its potential application in regenerative medicine.

Somatic Stem cells anticancer therapies embryonic stem cells pluripotent stem cells regenerative medicine stem cell differentiation stem cell proliferation tissue homeostasis

Link:
Somatic Stem Cells | SpringerLink

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health – Yahoo Finance

By Stell Cell Research

Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals. Boehringer Ingelheim already entered into a partnership with GST in 2018; in 2019, the companies launched Arti-Cell Forte in Europe.

Arti-Cell Forte is testimony to the innovation strength that lies within both companies. It is the first-ever stem cell product in the veterinary world granted marketing authorization by the European Commission. The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.

"Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the art stem cell products will help us bring even more innovative solutions to our customers," shares Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health.

"Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GSTs management, staff and vision. From the very beginning we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim," says Jan Spaas, CEO of GST.

"This decision is fully aligned with our recently refocused strategic direction. Stem cell research areas and regenerative medicine offer an exciting potential for the next wave of innovation we are actively pursuing. In addition, strengthening external partnerships to accelerate our innovative efforts and growth is one of the key elements of our strategy," adds Eric Haaksma, Head of Global Innovation at Boehringer Ingelheim Animal Health.

The companies did not disclose the financial terms of the deal.

For references and notes to editors, please visit:

http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-global-stem-cell-technology

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005234/en/

Contacts

Boehringer Ingelheim Animal Health Communication Tereza Urbankova 552 16 Ingelheim, Germany Phone: +49 6132 77 184817 Email: press@boehringer-ingelheim.com

The rest is here:
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health - Yahoo Finance

Human Embryonic Stem Cells (HESC) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026|ESI BIO, Thermo Fisher, BioTime -…

By Stell Cell Research

QY Research has Published Latest Trending Report on Global Human Embryonic Stem Cells (HESC) Market

Los Angeles, United State, The report titledGlobal Human Embryonic Stem Cells (HESC) Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Human Embryonic Stem Cells (HESC) market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Human Embryonic Stem Cells (HESC) market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Human Embryonic Stem Cells (HESC) market is carefully analyzed and researched about by the market analysts.

Request Sample Report and Full Report TOC:https://www.qyresearch.com/sample-form/form/1749373/covid-19-impact-on-human-embryonic-stem-cells-hesc-market

The Essential Content Covered in the GlobalHuman Embryonic Stem Cells (HESC) Market Report:

* Top Key Company Profiles. * Main Business and Rival Information * SWOT Analysis and PESTEL Analysis * Production, Sales, Revenue, Price and Gross Margin * Market Share and Size

Global Human Embryonic Stem Cells (HESC) Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Human Embryonic Stem Cells (HESC) market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Top Players of Human Embryonic Stem Cells (HESC) Market are Studied: ESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolife, etc.

The report provides a 6-year forecast (2020-2026) assessed based on how the Human Embryonic Stem Cells (HESC) market is predicted to grow in major regions likeUSA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Segmentation by Type:, Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells

Segmentation by Application:, Research, Clinical Trials, Others

Reasons to Buy this Report:

Table of Contents

1.1 Research Scope 1.2 Market Segmentation 1.3 Research Objectives 1.4 Research Methodology 1.4.1 Research Process 1.4.2 Data Triangulation 1.4.3 Research Approach 1.4.4 Base Year 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 1.5.2 Covid-19 Impact: Commodity Prices Indices 1.5.3 Covid-19 Impact: Global Major Government Policy 1.6 The Covid-19 Impact on Car Sealed lead-acid Battery Industry 1.7 COVID-19 Impact: Car Sealed lead-acid Battery Market Trends 2 Global Car Sealed lead-acid Battery Quarterly Market Size Analysis 2.1 Car Sealed lead-acid Battery Business Impact Assessment COVID-19 2.1.1 Global Car Sealed lead-acid Battery Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.1.2 Global Car Sealed lead-acid Battery Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.2 Global Car Sealed lead-acid Battery Quarterly Market Size 2020-2021 2.3 COVID-19-Driven Market Dynamics and Factor Analysis 2.3.1 Drivers 2.3.2 Restraints 2.3.3 Opportunities 2.3.4 Challenges 3 Quarterly Competitive Assessment, 2020 3.1 Global Car Sealed lead-acid Battery Quarterly Market Size by Manufacturers, 2019 VS 2020 3.2 Global Car Sealed lead-acid Battery Factory Price by Manufacturers 3.3 Location of Key Manufacturers Car Sealed lead-acid Battery Manufacturing Factories and Area Served 3.4 Date of Key Manufacturers Enter into Car Sealed lead-acid Battery Market 3.5 Key Manufacturers Car Sealed lead-acid Battery Product Offered 3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Car Sealed lead-acid Battery Segments, By Type 4.1 Introduction 1.4.1 AGM Battery 1.4.2 Gel Battery 4.2 By Type, Global Car Sealed lead-acid Battery Market Size, 2019-2021 4.2.1 By Type, Global Car Sealed lead-acid Battery Market Size by Type, 2020-2021 4.2.2 By Type, Global Car Sealed lead-acid Battery Price, 2020-2021 5 Impact of Covid-19 on Car Sealed lead-acid Battery Segments, By Application 5.1 Overview 5.5.1 Passenger Vehicle 5.5.2 Commercial Vehicle 5.2 By Application, Global Car Sealed lead-acid Battery Market Size, 2019-2021 5.2.1 By Application, Global Car Sealed lead-acid Battery Market Size by Application, 2019-2021 5.2.2 By Application, Global Car Sealed lead-acid Battery Price, 2020-2021 6 Geographic Analysis 6.1 Introduction 6.2 North America 6.2.1 Macroeconomic Indicators of US 6.2.2 US 6.2.3 Canada 6.3 Europe 6.3.1 Macroeconomic Indicators of Europe 6.3.2 Germany 6.3.3 France 6.3.4 UK 6.3.5 Italy 6.4 Asia-Pacific 6.4.1 Macroeconomic Indicators of Asia-Pacific 6.4.2 China 6.4.3 Japan 6.4.4 South Korea 6.4.5 India 6.4.6 ASEAN 6.5 Rest of World 6.5.1 Latin America 6.5.2 Middle East and Africa 7 Company Profiles 7.1 Johnson Controls 7.1.1 Johnson Controls Business Overview 7.1.2 Johnson Controls Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.1.3 Johnson Controls Car Sealed lead-acid Battery Product Introduction 7.1.4 Johnson Controls Response to COVID-19 and Related Developments 7.2 GS Yuasa 7.2.1 GS Yuasa Business Overview 7.2.2 GS Yuasa Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.2.3 GS Yuasa Car Sealed lead-acid Battery Product Introduction 7.2.4 GS Yuasa Response to COVID-19 and Related Developments 7.3 Exide Technologies 7.3.1 Exide Technologies Business Overview 7.3.2 Exide Technologies Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.3.3 Exide Technologies Car Sealed lead-acid Battery Product Introduction 7.3.4 Exide Technologies Response to COVID-19 and Related Developments 7.4 Hitachi Chemical 7.4.1 Hitachi Chemical Business Overview 7.4.2 Hitachi Chemical Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.4.3 Hitachi Chemical Car Sealed lead-acid Battery Product Introduction 7.4.4 Hitachi Chemical Response to COVID-19 and Related Developments 7.5 Camel Group 7.5.1 Camel Group Business Overview 7.5.2 Camel Group Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.5.3 Camel Group Car Sealed lead-acid Battery Product Introduction 7.5.4 Camel Group Response to COVID-19 and Related Developments 7.6 Sebang 7.6.1 Sebang Business Overview 7.6.2 Sebang Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.6.3 Sebang Car Sealed lead-acid Battery Product Introduction 7.6.4 Sebang Response to COVID-19 and Related Developments 7.7 Atlas BX 7.7.1 Atlas BX Business Overview 7.7.2 Atlas BX Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.7.3 Atlas BX Car Sealed lead-acid Battery Product Introduction 7.7.4 Atlas BX Response to COVID-19 and Related Developments 7.8 CSIC Power 7.8.1 CSIC Power Business Overview 7.8.2 CSIC Power Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.8.3 CSIC Power Car Sealed lead-acid Battery Product Introduction 7.8.4 CSIC Power Response to COVID-19 and Related Developments 7.9 East Penn 7.9.1 East Penn Business Overview 7.9.2 East Penn Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.9.3 East Penn Car Sealed lead-acid Battery Product Introduction 7.9.4 East Penn Response to COVID-19 and Related Developments 7.10 Banner Batteries 7.10.1 Banner Batteries Business Overview 7.10.2 Banner Batteries Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.10.3 Banner Batteries Car Sealed lead-acid Battery Product Introduction 7.10.4 Banner Batteries Response to COVID-19 and Related Developments 7.11 Chuanxi Storage 7.11.1 Chuanxi Storage Business Overview 7.11.2 Chuanxi Storage Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.11.3 Chuanxi Storage Car Sealed lead-acid Battery Product Introduction 7.11.4 Chuanxi Storage Response to COVID-19 and Related Developments 7.12 Exide Industries 7.12.1 Exide Industries Business Overview 7.12.2 Exide Industries Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.12.3 Exide Industries Car Sealed lead-acid Battery Product Introduction 7.12.4 Exide Industries Response to COVID-19 and Related Developments 7.13 Ruiyu Battery 7.13.1 Ruiyu Battery Business Overview 7.13.2 Ruiyu Battery Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.13.3 Ruiyu Battery Car Sealed lead-acid Battery Product Introduction 7.13.4 Ruiyu Battery Response to COVID-19 and Related Developments 7.14 Amara Raja 7.14.1 Amara Raja Business Overview 7.14.2 Amara Raja Car Sealed lead-acid Battery Quarterly Production and Revenue, 2020 7.14.3 Amara Raja Car Sealed lead-acid Battery Product Introduction 7.14.4 Amara Raja Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis 8.1 Car Sealed lead-acid Battery Supply Chain Analysis 8.1.1 Car Sealed lead-acid Battery Supply Chain Analysis 8.1.2 Covid-19 Impact on Car Sealed lead-acid Battery Supply Chain 8.2 Distribution Channels Analysis 8.2.1 Car Sealed lead-acid Battery Distribution Channels 8.2.2 Covid-19 Impact on Car Sealed lead-acid Battery Distribution Channels 8.2.3 Car Sealed lead-acid Battery Distributors 8.3 Car Sealed lead-acid Battery Customers 9 Key Findings 10 Appendix 10.1 About Us 10.2 Disclaimer

About US

QY Research is a leading global market research and consulting company. Established in 2007 in Beijing, China, QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services.

Link:
Human Embryonic Stem Cells (HESC) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026|ESI BIO, Thermo Fisher, BioTime -...

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – Business Wire

By Stem Cell Treatment

CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620) and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avactas neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future global pandemics.

Respiratory diseases such as COVID-19 can cause serious damage to the lungs as a consequence of over-activation of the patient's immune system, resulting in cytokine release syndrome that can potentially lead to multiple organ failure and death. Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance.

AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong Pharmaceutical, is developing a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action.

The expansion of the agreement between Avacta, Daewoong Pharmaceutical and AffyXell announced today extends the scope of the partnership to include Affimer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by COVID-19 whilst also producing neutralising Affimer molecules to prevent the progression of the disease.

AffyXell will engineer mesenchymal stem cells to express SARS-COV-2 neutralising Affimer molecules in order to develop treatments for seriously ill COVID-19 patients, and will also prepare for rapid development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.

Dr. Alastair Smith, Chief Executive of Avacta Group commented: I am very pleased to have extended our collaboration and license agreement with Daewoong Pharmaceutical to include the SARS-COV-2 neutralising Affimer molecules for the treatment of COVID-19 and to create the potential to respond very rapidly in future to global virus threats.

AffyXell will address the need over the coming years for advanced stem cell therapies to treat lung damage caused by cytokine release syndrome suffered by COVID-19 patients and, at the same time, help prevent disease progression in these patients through the action of a neutralising Affimer therapy.

More broadly, one of the key areas of unmet clinical need that AffyXell can address with its next-generation mesenchymal stem cell therapies is acute pulmonary diseases such as COPD and acute respiratory distress syndrome. We, and our partners in South Korea, are very excited by the potential to develop life improving treatments for patients with these serious respiratory diseases as well as COVID-19.

I look forward to further updating the market on progress in our ground-breaking programmes with AffyXell in due course, and on progress with our COVID-19 diagnostics programmes shortly.

Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, commented:

It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses. The SARS-COV-2 neutralising Affimer to be developed in combination with AffyXells cell and gene technology is expected to be an innovative solution for COVID-19 patients suffering cytokine release syndrome.

Daewoong has been also conducting several research programs and clinical trial for COVID-19. As the COVID-19 crisis has caused great difficulties worldwide, we will continue to focus our efforts to develop a novel therapeutic agent for COVID-19.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

See the original post:
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy - Business Wire

FDA Approves New CAR-T Therapy for Mantle Cell Lymphoma – Cancer Health Treatment News

By Stem Cell Treatment

On July 24, the Food and Drug Administration (FDA) granted accelerated approval of a new CAR-T therapy, Tecartus (brexucabtagene autoleucel), for adults with mantle cell lymphoma who have not responded to or who have relapsed after other kinds of treatment.

Tecartus (formerly known as KTE-X19), manufactured by Kite, a Gilead Company, is a living drug that reprograms a patients own T cells to fight cancer. About two thirds of participants treated in the ZUMA-2 study experienced complete remission, which in a majority of cases lasted at least a year.

"This approval is yet another example of customized treatments that use a patients own immune system to help fight cancer, Peter Marks, MD, PhD, director of the FDAs Center for Biologics Evaluation and Research, said in a press release. Were seeing continued advances in the field of gene therapy and remain committed to supporting innovation in this promising new area of medicine.

Mantle cell lymphoma (MCL) is an uncommon form of non-Hodgkinlymphoma that involves overgrowth of abnormal B cells in lymph nodes. By the time it is diagnosed, MCL has often spread to the bone marrow and other organs, and it is frequently refractory (nonresponsive) to existing treatments or relapses following a period of remission.

Chimeric antigen receptor T-cell therapybetter known as CAR-Tinvolves removing a sample of a patients white blood cells, genetically reprogramming the T cells to recognize and attack their cancer, manufacturing a large number of the modified cells in a laboratory and infusing them back into the body. Like Kites previously approved CAR-T Yescarta (axicabtagene ciloleucel), Tecartus targets the CD19 protein on B cells, but the manufacturing process includes greater T-cell selection and lymphocyte enrichment.

The Phase II ZUMA-2 trial enrolled 74 adults with relapsed or refractory MCL in the United States and Europe who had previously tried up to five prior therapies. Six people ended up not receiving Tecartus because of manufacturing failures or death due to disease progression.

The primary analysis included 60 treated participants. Most were men, and the median age was 65. Most had Stage IV metastatic cancer, more than 80% had tried three or more prior treatments and 43% had received a bone marrow stem cell transplant.

A sample of the patients T cells were collected and modified, and they received strong conditioning chemotherapy to kill off some of their existing immune cells to make room for the new ones. They then received a single infusion of the genetically engineered cells.

As described at last years American Society of Hematology Annual Meeting and in The New England Journal of Medicine, the overall response rate, meaning complete or partial remission, was 93%, including 67% with complete responses. After a year of follow-up, 57% were still in remission, as were 43% of those followed for two years. The estimated one-year progression-free survival rate was 61%, and the estimated overall survival rate was 83%.

In a press release announcing the approval, Gilead/Kite gave an updated overall response rate of 87% and a complete response rate of 62%.

Therapies that receive FDA accelerated approval based on overall response rates are expected to undergo further testing in larger trials to confirm clinical benefits, and the agencycan rescind approval if they do not measure up. Tecartus is also currently in Phase I/II trials for acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Treatment with Tecartus was generally safe. The most common severe adverse events were low blood cell counts due to the conditioning chemotherapy and infections. Introducing engineered T cells can trigger a strong immune reaction known as cytokine release syndrome (CRS), which can lead to falling blood pressure and organ failure. As previously reported, 15% of study participants experienced Grade 3 or higher CRS, and 31% developed severe neurological side effects. Based on a larger group of patients, Gilead/Kite updated these figures to 18% and 37%, respectively. These side effects were managed with corticosteroids or Actemra (tocilizumab), and none were fatal.

A risk evaluation and mitigation strategy (REMS) for Tecartus has been approved by the FDA and combined with the YescartaREMS (www.YescartaTecartusREMS.com). This program informs health care professionals about the risks associated with CAR-T therapy and how to manage it.

Tecartus will be produced at Kites commercial manufacturing facility in El Segundo, California. The median turnaround time from T-cell collection to administration of the modified cells is around 15 days, according to the press release. The Kite Konnectprogram offers financial and logistical support for eligible patients receiving Tecartus or Yescarta.

Despite promising advances, there are still major gaps in treatment for patients with MCL who progress following initial therapy, ZUMA-2 lead investigator Michael Wang, MD, of University of Texas MD Anderson Cancer Center, said in the press release. Many patients have high-risk disease and are more likely to keep progressing, even after subsequent treatments. The availability of Tecartus as the first-ever cell therapy for patients with relapsed/refractory MCL provides an important option with a response rate of nearly 90% and early clinical evidence suggesting durable remissions in later lines of therapy.

Click here to learn more about lymphoma.

Original post:
FDA Approves New CAR-T Therapy for Mantle Cell Lymphoma - Cancer Health Treatment News

Distanced from a pricing controversy, Jeff Aronin steers one of his biotechs to Nasdaq with a familiar regulatory strategy tied to a big bet -…

By Stem Cell Clinic

Bob Nelsen had been quietly wondering how to eradicate viruses for years, before one day in 2015, he welcomed a pair of immunologists into the ARCH Venture Partners offices on the 34th floor of Seattles Wells Fargo Building.

Louis Picker and Klaus Frh, professors at Oregon Health & Science University, had by then spent 5 years running around the country in search of funding for their startup, TomegaVax, and Frh, at least, was nearing wits end. The Gates Foundation was interested but told them they needed other investors. Investors told them to come back with more data, pharmaceutical executives said theyre in the wrong game too little money to be made fighting infectious disease. Still, a well-connected board member named Bob More landed them a meeting with the coveted venture capitalist, and so, in a narrow conference room overlooking the Puget Sound, Picker prepared to again explain the idea he had spent 15 years on: re-engineering a benign microbe into the first vaccines for HIV and better ones for hepatitis and tuberculosis.

This lightbulb went on his head, Picker recalled in a recent interview. Most of them just didnt get it. And Bobs hit.

By that point, Nelsen was more than just a venture capitalist. Scraggly and greying but no less opinionated at 52, he was mobbed at biotech conferences, having earned a reputation for crass wisdom and uncanny foresight, for making big bets on big ideas that changed medicine. Those ideas included DNA sequencing, which he first cut a check for in the 90s, and leveraging the immune system to tackle cancer. He earned millions making billion-dollar companies.

Yet for years he had harbored an almost singular obsession: I hate viruses, he told Forbes in 2016. He told me he was pissed off at them. The obsession drove him to his first biotech investment in 1993, for an inhalable flu vaccine approved a decade later and still in use. And it drove him to invest in CAR-T as a potential cure for HIV, years before it proved a wildly effective treatment for some cancers.

Now, listening to Picker talk about T cells and antibodies and the curious biology of cytomegalovirus, Nelsen began wondering if it was time for another bet. Pickers technology was not only promising, he reasoned, it could be the basis of a company that changed how researchers approached viruses. Instead of trying to come up with an antidote for every pathogen, you could do what cancer researchers had learned to do, and harness the immune system to do the work for you.

This wasnt a popular opinion at the time. Its like the least trendy idea in the world, Nelsen told me. People would say, Why the hell are you going into infectious disease?

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Continued here:
Distanced from a pricing controversy, Jeff Aronin steers one of his biotechs to Nasdaq with a familiar regulatory strategy tied to a big bet -...

Genfit throws in the towel on NASH, exiting a tumultuous field full of bright market prospects and lethal R&D setbacks – Endpoints News

By Stem Cell Medicine

Bob Nelsen had been quietly wondering how to eradicate viruses for years, before one day in 2015, he welcomed a pair of immunologists into the ARCH Venture Partners offices on the 34th floor of Seattles Wells Fargo Building.

Louis Picker and Klaus Frh, professors at Oregon Health & Science University, had by then spent 5 years running around the country in search of funding for their startup, TomegaVax, and Frh, at least, was nearing wits end. The Gates Foundation was interested but told them they needed other investors. Investors told them to come back with more data, pharmaceutical executives said theyre in the wrong game too little money to be made fighting infectious disease. Still, a well-connected board member named Bob More landed them a meeting with the coveted venture capitalist, and so, in a narrow conference room overlooking the Puget Sound, Picker prepared to again explain the idea he had spent 15 years on: re-engineering a benign microbe into the first vaccines for HIV and better ones for hepatitis and tuberculosis.

This lightbulb went on his head, Picker recalled in a recent interview. Most of them just didnt get it. And Bobs hit.

By that point, Nelsen was more than just a venture capitalist. Scraggly and greying but no less opinionated at 52, he was mobbed at biotech conferences, having earned a reputation for crass wisdom and uncanny foresight, for making big bets on big ideas that changed medicine. Those ideas included DNA sequencing, which he first cut a check for in the 90s, and leveraging the immune system to tackle cancer. He earned millions making billion-dollar companies.

Yet for years he had harbored an almost singular obsession: I hate viruses, he told Forbes in 2016. He told me he was pissed off at them. The obsession drove him to his first biotech investment in 1993, for an inhalable flu vaccine approved a decade later and still in use. And it drove him to invest in CAR-T as a potential cure for HIV, years before it proved a wildly effective treatment for some cancers.

Now, listening to Picker talk about T cells and antibodies and the curious biology of cytomegalovirus, Nelsen began wondering if it was time for another bet. Pickers technology was not only promising, he reasoned, it could be the basis of a company that changed how researchers approached viruses. Instead of trying to come up with an antidote for every pathogen, you could do what cancer researchers had learned to do, and harness the immune system to do the work for you.

This wasnt a popular opinion at the time. Its like the least trendy idea in the world, Nelsen told me. People would say, Why the hell are you going into infectious disease?

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Read the original post:
Genfit throws in the towel on NASH, exiting a tumultuous field full of bright market prospects and lethal R&D setbacks - Endpoints News

Cell Proliferation Kit Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 – Owned

By Stell Cell Research

Cell Proliferation Kit Market

UpMarketResearch, 29-07-2020: The research report on the Cell Proliferation Kit Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a PDF Copy of the Sample Report for Free @ https://www.upmarketresearch.com/home/requested_sample/7038

The Major Manufacturers Covered in this Report: Biological Industries Thermo Fisher Scientific Sigma-Aldrich (Merck) BD Biosciences GE Healthcare PerkinElmer Millipoore (Merck) Bio-Rad Biotium Mindray Medical

The Research Study Focuses on:

By Types: Colorimetric Detection Method Fluorescent Detection Method Other

By Applications: Clinical Industrial & Applied Science Stem Cell Research

By Regions:

To get this report at incredible Discounts, visit @ https://www.upmarketresearch.com/home/request_for_discount/7038

The Cell Proliferation Kit Market Report Consists of the Following Points:

Make an Inquiry of the Cell Proliferation Kit Market Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/7038

In conclusion, the Cell Proliferation Kit Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

About UpMarketResearch: Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearch Name Alex Mathews Email [emailprotected] Organization UpMarketResearch Address 500 East E Street, Ontario, CA 91764, United States.

Read the rest here:
Cell Proliferation Kit Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 - Owned

R3 Stem Cell International Now Offering Four Joint Injections for Only $3950 in Mexico – Benzinga

By Stem Cell Treatment

SCOTTSDALE, Ariz., July 29, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell International is now offering patients the opportunity to receive four stem cell joint injections for only $3950. With 50 million stem cells total, patients may choose which extremities they would like treated.

Several studies have shown just how well stem cell therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with a long history of accreditation and pristine safety record. The lab abides by quality assurance standards that exceed those of the FDA.

Stem cell treatment for knees in Mexico at R3 works amazingly well. Patient satisfaction surveys at the center reveal that nine out of ten patients say they would have the procedure again and recommend it to friends and family.

According to R3 CEO David Greene, MD, MBA, "The biologics don't need preservative and viability exceeds 95%. The pureness and potency truly makes the difference in outcomes. Four joints for under $4000? What we put together for patients is incredible!"

The treatment process begins with a free phone consultation with one of R3's licensed, experienced stem cell doctors. Because the treatment includes 50 million stem cells, four joints may be included. The dedicated patient concierge representative assists with travel logistics. Travel from San Diego is included to the clinic, which is only 20 minutes from the San Diego airport.

Image guidance is used at the Center to ensure injection accuracy. In addition to arthritis treatment, R3 International offers stem cell treatment for autism, Lyme, COPD, kidney failure, neuropathy, diabetes, MS, ALS, stroke and much more.

Call (888) 988-0515 to learn more about therapies offered, and visit https://stemcelltreatmentclinic.com to read about the process.

SOURCE R3 Stem Cell International

See the rest here:
R3 Stem Cell International Now Offering Four Joint Injections for Only $3950 in Mexico - Benzinga

Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Bulletin Line

By Stem Cell Treatment

Global Stem Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Stem Cell Therapy market is anticipated to grow at large scale over the forecast period (2020-2025). The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world. Key drivers as well as challenges of the market are discussed in the report. Also reports provides an in depth analysis of the Stem Cell Therapy market with current and future trends.

Get Sample Copy of this Report:https://www.adroitmarketresearch.com/contacts/request-sample/691

In addition, study report offers an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global Stem Cell Therapy market. Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the market over the forecast period.

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Stem Cell Therapy market. The study report covers all the recent developments and innovations in the market for a Stem Cell Therapy. The global keyword market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market. These strategies have an impact on the overall market.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The research report on global Stem Cell Therapy market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Stem Cell Therapy market. Study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

In addition, report presents quantitative as well as qualitative narration of global Stem Cell Therapy market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts. Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Stem Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

For Any Query on the Stem Cell Therapy Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Continue reading here:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Bulletin Line

→←